CA-XYO-NETWORK
29.9.2021 01:58:07 CEST | Business Wire | Press release
The XYO Network (Coinbase: $XYO), the geospatial blockchain network, announced today a recent record 2x growth as well as profitability for the first half of 2021. XY Labs generated net income of $3,841,615 in the first half of 2021 through a plethora of disclosed and undisclosed partnerships vs a loss of $1,967,793 in the first half of 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006178/en/
XYO stated that the number of nodes for the XYO Network had doubled in size over the last three months, noting a promising outlook for the remaining 2021 year and emphasizing a strong recovery from the global lull caused by COVID-19.
The company’s announcement shines a light on the constant financial struggle for many crypto-projects, whose main assets like crypto tokens and currencies experience extreme volatility on the decentralized exchanges they trade on. Arie Trouw, one of the project’s founders and CEO of the parent company explained how XYO avoided becoming a “dead coin ” by focusing on profitability and technological development over the past two years.
“Unlike many ‘dead coins’ that arose from failed crypto-projects from 2018, our utility token has been thriving,” Trouw said. “We believe that by choosing to focus deeply on solid technology, profitability, and developmental growth over the last two years, we have surpassed other blockchain projects that may focus more on the excitement of growth and promises.”
Trouw went on to explain some of the upcoming updates to the XYO Network technology, highlighting a goal to improve the speed and implementation of future and current partnerships.
This isn’t the first time the company has shared exciting numbers about their products; earlier this year they released a case study that analyzed 500 customers who use their “COIN” App product to participate in the blockchain network in exchange for prizes and rewards. The study showed how the users had collectively earned 933,697,010 XYO Tokens, the crypto utility token used for the network that was recently listed on Coinbase. At the time of the case study, the total tokens were valued at over $14 million.
Trouw stated there is more to come and is hopeful for the upcoming developments. “Over the last two years we may have been quieter, but by no means less focused on bringing to life the technology we’ve dreamed of building,” he stated. “If anything, we’ve been more efficient and more aligned than ever… and we can’t wait to see where it all goes next.”
More Information about XY Labs and XYO Network
Since 2012, we've developed geospatial products for customers to use in everyday life that help them improve the creation, management, and provenance of their personal activities, tasks, entertainment, and data. In 2018, we unveiled the XYO Network, the world’s first geospatial blockchain network backed with cryptography. With over 3 million downloads for our XYO-enabled application “COIN”, users around the world can participate in the XYO Network and even be rewarded for doing so. For more information, visit us at https://xy.company and https://xyo.network .
Facebook: www.facebook.com/OfficialXYO
Instagram: www.instagram.com/officialxyo
Twitter: www.twitter.com/officialxyo
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006178/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom